Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Ebola vaccine prime-boost regimens (Ad26.ZEBOV + MVA-BN-Filo) in healthy adults in Europe
2015-000596-27Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2015
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of zabdeno and Mvabea in Ebola virus disease (EVD) (4 arms), sponsored by Johnson & Johnson. Primary endpoint: Number of Participants With Adverse Events. Started Jul 2015; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on 2015-000596-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000596-27.